Pipeline

EU103
Indication Solid tumor Target /Drug class Anti-human VSIG4 mAb Development Stage Non-clinical
Summary
  • Humanized monoclonal antibody of the engineered IgG1/kappa
  • Immunotherapeutic, anti-human VSIG4 antibody
  • Regulator of macrophage differentiation : regulator of typeⅡ macrophage conversion
  • Blockade of inhibition of cytotoxic T cell
In vitro/in vivo Efficacy
Mode of Action

1 Induces CD＋ T cell proliferation for enhanced cytotoxicity

2 Converts suppressive M2 to M1 macrophage for inprovement of tumor microenvironment